• Paulo Gustavo Kotze, Takayuki Yamamoto, Silvio Danese, Yasuo Suzuki, Fabio Vieira Teixeira, Idblan Carvalho de Albuquerque, Rogerio Saad-Hossne, Ivan Folchini de Barcelos, Rodolff Nunes da Silva, Lorete Ma... more ria da Silva Kotze, Márcia Olandoski, Matteo Sacchi, Akihiro Yamada, Ken Takeuchi, and Antonino Spinelli. less
• Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, Brazil pgkotze@hotmail.com.
• J Crohns Colitis. 2015 Jul 1; 9 (7): 541-7.

Background And AimsBoth adalimumab [ADA] and infliximab [IFX] seem to be effective in the prevention of early postoperative endoscopic recurrence [EPER] after ileocaecal resection in Crohn's disease [CD] patients. There is lack of data with direct comparison between the two agents in the postoperative scenario. The aim of this study was to compare the rates of EPER in patients treated with ADA and IFX after ileocaecal resection for CD.MethodsThis was a multicentre retrospective analysis of EPER rates in CD patients after ileocaecal resections, from seven referral centres in three countries. Endoscopic recurrence was defined as Rutgeerts' score ≥ i2. The patients were allocated according to treatment to two groups: ADA or IFX. The EPER rates were compared between the two treatment groups.ResultsAmong the 168 patients included in the database, 96 received anti-tumour necrosis factor [TNF] agents after resection [37 in the ADA and 59 in the IFX groups] and were included in this comparative study. The groups were comparable in all baseline characteristics, mainly age, gender, previous resections, perianal CD, and mono or combination therapy. EPER was identified in 9/37 [24.32%] in the ADA group vs 16/59 [27.12%] in the IFX group [p = 0.815].ConclusionsIn this retrospective direct comparison between ADA and IFX therapy after ileocaecal resection, there was no significant difference between the two anti-TNF agents in terms of EPER rates. However, prospective randomised studies are needed to confirm these data and better define the role of each agent in the prevention of EPER.Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

33 keywords...

hide…